Nantahala Capital discloses 6.37% Korro Bio (KRRO) stake in Schedule 13G

Rhea-AI Filing Summary

Nantahala Capital Management, LLC and its principals reported a significant ownership stake in Korro Bio, Inc. As of December 31, 2025, they may be deemed to beneficially own 600,000 shares of Korro Bio common stock, representing 6.37% of the outstanding shares.

The shares are held by funds and separately managed accounts under Nantahala’s control, with Nantahala, Wilmot B. Harkey, and Daniel Mack sharing voting and dispositive power over all 600,000 shares. They state that the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Korro Bio.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Korro Bio, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

500946108

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 500946108

1

Names of Reporting Persons

Nantahala Capital Management, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

MASSACHUSETTS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 600,000.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 600,000.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

600,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.37 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

CUSIP No. 500946108

1

Names of Reporting Persons

Wilmot B. Harkey

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 600,000.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 600,000.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

600,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.37 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

CUSIP No. 500946108

1

Names of Reporting Persons

Daniel Mack

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 600,000.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 600,000.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

600,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.37 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Korro Bio, Inc.
(b)	Address of issuer's principal executive offices: 60 FIRST STREET 2ND FLOOR, SUITE 250 CAMBRIDGE, MASSACHUSETTS, 02141
Item 2.
(a)	Name of person filing: (1) Nantahala Capital Management, LLC ("Nantahala") (2) Wilmot B. Harkey (3) Daniel Mack (together the "Reporting Persons")
(b)	Address or principal business office or, if none, residence: 130 Main St. 2nd Floor, New Canaan, Connecticut 06840
(c)	Citizenship: (1) Nantahala is a Massachusetts limited liability company. (2) Each of Messrs. Harkey and Mack is a citizen of the United States of America.
(d)	Title of class of securities: Common Stock, par value $0.001 per share
(e)	CUSIP No.: 500946108
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: As of December 31, 2025, Nantahala may be deemed to be the beneficial owner of 600,000 Shares held by funds and separately managed accounts under its control, and as the managing members of Nantahala, each of Messrs. Harkey and Mack may be deemed to be a beneficial owner of those Shares.
(b)	Percent of class: As of December 31, 2025, each of the Reporting Persons may be deemed to be the beneficial owner of the following percentage of the total number of Shares outstanding: (1) Nantahala Capital Management, LLC ("Nantahala") : 6.37% (2) Wilmot B. Harkey: 6.37% (3) Daniel Mack: 6.37%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: (1) Nantahala Capital Management, LLC ("Nantahala") : 0 Shares. (2) Wilmot B. Harkey: 0 Shares. (3) Daniel Mack: 0 Shares.
	(ii) Shared power to vote or to direct the vote: (1) Nantahala Capital Management, LLC ("Nantahala") : 600,000 Shares. (2) Wilmot B. Harkey: 600,000 Shares. (3) Daniel Mack: 600,000 Shares.
	(iii) Sole power to dispose or to direct the disposition of: (1) Nantahala Capital Management, LLC ("Nantahala") : 0 Shares. (2) Wilmot B. Harkey: 0 Shares. (3) Daniel Mack: 0 Shares.
	(iv) Shared power to dispose or to direct the disposition of: (1) Nantahala Capital Management, LLC ("Nantahala") : 600,000 Shares. (2) Wilmot B. Harkey: 600,000 Shares. (3) Daniel Mack: 600,000 Shares.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. Each of Messrs. Harkey and Mack is filing this Schedule 13G as a control person in respect of shares beneficially owned by Nantahala, an investment adviser as described in ss. 240.13d-1(b)(1)(ii)(E). See Item 4(a).
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Nantahala Capital Management, LLC

Signature:	/s/ Taki Vasilakis
Name/Title:	Taki Vasilakis / Chief Compliance Officer
Date:	02/13/2026

Wilmot B. Harkey

Signature:	/s/ Wilmot B. Harkey
Name/Title:	Wilmot B. Harkey
Date:	02/13/2026

Daniel Mack

Signature:	/s/ Daniel Mack
Name/Title:	Daniel Mack
Date:	02/13/2026

FAQ

What stake in Korro Bio (KRRO) does Nantahala Capital report on this Schedule 13G?

Nantahala Capital and its principals report beneficial ownership of 600,000 Korro Bio common shares, equal to 6.37% of the class as of December 31, 2025. The shares are held across funds and separately managed accounts under Nantahala’s control.

Who are the reporting persons on this Korro Bio (KRRO) Schedule 13G filing?

The reporting persons are Nantahala Capital Management, LLC, and its managing members Wilmot B. Harkey and Daniel Mack. Each may be deemed a beneficial owner of the same 600,000 Korro Bio common shares through funds and accounts managed by Nantahala.

How much voting power do the reporting persons have over Korro Bio (KRRO) shares?

Each reporting person reports zero sole voting power and shared voting power over 600,000 Korro Bio common shares. They also report zero sole dispositive power and shared dispositive power over the same 600,000 shares held in managed funds and accounts.

As of what date is the Korro Bio (KRRO) ownership percentage calculated in this Schedule 13G?

The 6.37% ownership figure for Korro Bio is calculated as of December 31, 2025. On that date, the reporting persons may be deemed to beneficially own 600,000 shares of Korro Bio common stock through funds and accounts managed by Nantahala.

Is Nantahala Capital seeking to influence control of Korro Bio (KRRO) with this stake?

The reporting persons certify the Korro Bio shares were acquired and are held in the ordinary course of business. They state the holdings are not for the purpose of changing or influencing control of Korro Bio, except for activities solely related to a nomination under Rule 240.14a-11.

What type of security in Korro Bio (KRRO) is covered by this Schedule 13G?

The filing covers Korro Bio’s common stock with a par value of $0.001 per share, identified by CUSIP 500946108. The reporting persons collectively report beneficial ownership and shared voting and dispositive power over 600,000 shares of this common stock.